Document is current
Any future updates will be listed below
-
Authors
Muik, Alexander
Adams, Homer C 3rd
Gieseke, Friederike
Altintas, Isil
Schoedel, Kristina B
Blum, Jordan M
Sänger, Bianca
Burm, Saskia M
Stanganello, Eliana
Verzijl, Dennis
Spires, Vanessa M
Vascotto, Fulvia
Toker, Aras https://orcid.org/0000-0001-6601-0939
Quinkhardt, Juliane
Fereshteh, Mark
Diken, Mustafa
Satijn, David P E
Kreiter, Sebastian
Ahmadi, Tahamtan
Breij, Esther C W
Türeci, Özlem
Sasser, Kate
Sahin, Ugur
Jure-Kunkel, Maria
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04083599 at ClinicalTrials.govnct04083599 at ClinicalTrials.govDocuments that mention this clinical trial
493 First-in-human phase 1/2 trial to evaluate the safety and initial clinical activity of DuoBody®-CD40×4–1BB (GEN1042) in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2021-sitc2021.493
DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity
https://doi.org/10.1136/jitc-2021-004322
1181 GEN1042-mIgG2a, an Fc-inert mouse-human chimeric variant of GEN1042 (DuoBody<sup>®</sup>-CD40x4–1BB), exhibits <i>in vivo</i> antitumor activity and peripheral immune modulation
https://doi.org/10.1136/jitc-2023-sitc2023.1181
nct04083599 at ClinicalTrials.govDocuments that mention this clinical trial
493 First-in-human phase 1/2 trial to evaluate the safety and initial clinical activity of DuoBody®-CD40×4–1BB (GEN1042) in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2021-sitc2021.493
DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity
https://doi.org/10.1136/jitc-2021-004322
1181 GEN1042-mIgG2a, an Fc-inert mouse-human chimeric variant of GEN1042 (DuoBody<sup>®</sup>-CD40x4–1BB), exhibits <i>in vivo</i> antitumor activity and peripheral immune modulation
https://doi.org/10.1136/jitc-2023-sitc2023.1181
nct04083599 at ClinicalTrials.govDocuments that mention this clinical trial
493 First-in-human phase 1/2 trial to evaluate the safety and initial clinical activity of DuoBody®-CD40×4–1BB (GEN1042) in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2021-sitc2021.493
DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity
https://doi.org/10.1136/jitc-2021-004322
1181 GEN1042-mIgG2a, an Fc-inert mouse-human chimeric variant of GEN1042 (DuoBody<sup>®</sup>-CD40x4–1BB), exhibits <i>in vivo</i> antitumor activity and peripheral immune modulation
https://doi.org/10.1136/jitc-2023-sitc2023.1181
nct04083599 at ClinicalTrials.govDocuments that mention this clinical trial
493 First-in-human phase 1/2 trial to evaluate the safety and initial clinical activity of DuoBody®-CD40×4–1BB (GEN1042) in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2021-sitc2021.493
DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity
https://doi.org/10.1136/jitc-2021-004322
1181 GEN1042-mIgG2a, an Fc-inert mouse-human chimeric variant of GEN1042 (DuoBody<sup>®</sup>-CD40x4–1BB), exhibits <i>in vivo</i> antitumor activity and peripheral immune modulation
https://doi.org/10.1136/jitc-2023-sitc2023.1181
nct04083599 at ClinicalTrials.govDocuments that mention this clinical trial
493 First-in-human phase 1/2 trial to evaluate the safety and initial clinical activity of DuoBody®-CD40×4–1BB (GEN1042) in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2021-sitc2021.493
DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity
https://doi.org/10.1136/jitc-2021-004322
1181 GEN1042-mIgG2a, an Fc-inert mouse-human chimeric variant of GEN1042 (DuoBody<sup>®</sup>-CD40x4–1BB), exhibits <i>in vivo</i> antitumor activity and peripheral immune modulation
https://doi.org/10.1136/jitc-2023-sitc2023.1181
Documents that mention this clinical trial
493 First-in-human phase 1/2 trial to evaluate the safety and initial clinical activity of DuoBody®-CD40×4–1BB (GEN1042) in patients with advanced solid tumors
https://doi.org/10.1136/jitc-2021-sitc2021.493
DuoBody-CD40x4-1BB induces dendritic-cell maturation and enhances T-cell activation through conditional CD40 and 4-1BB agonist activity
https://doi.org/10.1136/jitc-2021-004322
1181 GEN1042-mIgG2a, an Fc-inert mouse-human chimeric variant of GEN1042 (DuoBody<sup>®</sup>-CD40x4–1BB), exhibits <i>in vivo</i> antitumor activity and peripheral immune modulation
https://doi.org/10.1136/jitc-2023-sitc2023.1181
- License Information
